Literature DB >> 20950167

Teriparatide therapy for alendronate-associated osteonecrosis of the jaw.

Ada Cheung, Ego Seeman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20950167     DOI： 10.1056/NEJMc1002684

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  46 in total

Review 1.  Lack of response to teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw.

Authors:  J Narváez; J A Narváez; C Gómez-Vaquero; J M Nolla
Journal:  Osteoporos Int       Date:  2012-03-08       Impact factor: 4.507

2.  Teriparatide's role in the management of bisphosphonate-associated osteonecrosis of the jaw.

Authors:  G Subramanian; S Y P Quek
Journal:  Osteoporos Int       Date:  2012-03-10       Impact factor: 4.507

Review 3.  Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015.

Authors:  A Khan; A Morrison; A Cheung; W Hashem; J Compston
Journal:  Osteoporos Int       Date:  2015-10-22       Impact factor: 4.507

Review 4.  Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.

Authors:  Robert A Adler; Ghada El-Hajj Fuleihan; Douglas C Bauer; Pauline M Camacho; Bart L Clarke; Gregory A Clines; Juliet E Compston; Matthew T Drake; Beatrice J Edwards; Murray J Favus; Susan L Greenspan; Ross McKinney; Robert J Pignolo; Deborah E Sellmeyer
Journal:  J Bone Miner Res       Date:  2016-01       Impact factor: 6.741

5.  A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration.

Authors:  Y Ohbayashi; A Iwasaki; F Nakai; T Mashiba; M Miyake
Journal:  Osteoporos Int       Date:  2019-11-25       Impact factor: 4.507

Review 6.  Current Status of Bone-Forming Therapies for the Management of Osteoporosis.

Authors:  Anne Sophie Koldkjær Sølling; Torben Harsløf; Bente Langdahl
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

Review 7.  Anabolic agents: what is beyond osteoporosis?

Authors:  Y Liu; A E Levack; E Marty; O Or; B P Samuels; M Redko; J M Lane
Journal:  Osteoporos Int       Date:  2018-04-07       Impact factor: 4.507

Review 8.  Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.

Authors:  Peter K Wong; Gelsomina L Borromeo; John D Wark
Journal:  Rheumatol Int       Date:  2013-05-08       Impact factor: 2.631

9.  Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw.

Authors:  K M Kim; W Park; S Y Oh; H-J Kim; W Nam; S-K Lim; Y Rhee; I H Cha
Journal:  Osteoporos Int       Date:  2014-02-20       Impact factor: 4.507

10.  Tooth extraction in mice administered zoledronate increases inflammatory cytokine levels and promotes osteonecrosis of the jaw.

Authors:  Tomoya Soma; Ryotaro Iwasaki; Yuiko Sato; Tami Kobayashi; Satoshi Nakamura; Yosuke Kaneko; Eri Ito; Hiroyuki Okada; Hisato Watanabe; Kana Miyamoto; Morio Matsumoto; Masaya Nakamura; Seiji Asoda; Hiromasa Kawana; Taneaki Nakagawa; Takeshi Miyamoto
Journal:  J Bone Miner Metab       Date:  2020-11-17       Impact factor: 2.626
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.